Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
In today’s financial news, Cathie Wood’s ARK ETFs have once again made significant strides in the biotech and technology sector. The daily trading report for Friday, December 20, 2024 shows a continued pattern of investment in genomic health companies and a notable sell-off in a leading electric vehicle maker.
The largest transaction of the day involved the purchase of 218,758 shares of Intellia Therapeutics Inc (NASDAQ:), split between the ARKK and ARKG ETFs, with a total value of $2,642,596. This move underscores ARK’s continued focus on companies with disruptive potential in the healthcare space, as Intellia is known for its leading work in CRISPR gene editing technology.
In terms of dollar value, ARK followed closely behind and also strengthened its position in 10X Genomics Inc (NASDAQ:) by purchasing 161,769 shares of ARKK and ARKG ETFs, valued at a total of $2,201,676. The company, which specializes in gene sequencing technology, is another integral part of ARK’s investment strategy.
On the sell side, ARK divested of 5,168 shares of Tesla Inc (NASDAQ:) from its ARKK ETF worth $2,254,126. This sale is part of a recent trend, as ARK reduced its stake in Tesla last week, even though the electric vehicle maker had played a central role in ARK’s portfolio in recent years.
Additionally, ARK sold 42,928 shares of Veracyte Inc (NASDAQ:), a genomic diagnostics company, through its ARKG ETF for an amount of $1,677,196. This trade could indicate a strategic shift or realignment within the genomics portion of the ARK portfolio.
In other activities, ARK invested in California Inc’s (NASDAQ:PACB) Pacific Biosciences (NASDAQ:) and purchased a total of 513,224 shares of ARKK and ARKG ETFs with a dollar value of $990,522. PACB, known for its long-read sequencing technologies, has been another consistent addition to ARK’s investments, suggesting an optimistic stance on the company’s growth prospects.
The day’s remaining trades included smaller selloffs, such as 49 shares of Senti Biosciences Inc (NASDAQ:SNTI) via ARKG ETF for a modest $195. Despite the small size, these transactions are part of ARK’s daily adjustments to optimize fund performance.
Looking at ARK’s trading patterns over the past week, the focus is clearly on genomic health companies, with repeat investments in Intellia Therapeutics, Pacific Biosciences and 10X Genomics. Conversely, the gradual reduction of Tesla holdings could signal a strategic reallocation of resources within ARK’s investment philosophy.
Investors and market watchers will continue to watch Cathie Wood’s ARK ETFs for insights into the disruptive innovation sectors and how these daily trades could shape the future of technology and healthcare investing.
This article was created with the assistance of AI and reviewed by an editor. Further information can be found in our terms and conditions.
